

Table 1. The patients' clinical characteristics (n = 77)

Characteristics	
Age, median [range] (years)	10[5,18]
Sex	
Male, n (%)	45 (58.4%)
Female, n (%)	32 (41.6%)
Start dosage of Thalidomide, mean (95%CI) [g/(kg·d)]	2.62 (2.42, 2.82)
Dosage of Thalidomide after third month visit, mean (95%CI) [g/(kg·d)]	3.61 (3.36, 3.85)
Genotype category	
β^0/β^0 , n (%)	21 (27.3%)
β^0/β^+ , n (%)	29 (37.7%)
β^+/β^+ , n (%)	27 (35.0%)
Transfusion volume before Thalidomide treatment, mean (95%CI) [ml/(kg.month)]	23.55 (21.32, 25.79)
Transfusion interval	
≥ 28 days, n (%)	18 (23.4%)
< 28 days, n (%)	59 (76.6%)
Combined with AIHA, n (%)	3 (3.9%)

Splenectomy before, n (%)

3 (3.9%)

Baseline HbF, mean (95%CI) (g/L)

8.44 (6.72, 10.17)

* abbreviation: AIHA, autoimmune hemolytic anemia; HbF, fetal hemoglobin

Complete deficiency of β -globin is regarded as β^0 and partial β -globin deficiency is regarded as β^+ .